ArticleNPJ precision oncology2022

Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients.

Chi Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.